Sorrento Therapeutics Stock Price and Value Analysis

Should you buy Sorrento Therapeutics stock? (NasdaqCM:SRNE). Let's see how it does in our automated value investing analysis system.

SRNE Free Cash Flow Trend

Free Cash Flow trendline for SRNE
Free Cash Flow trendline for Sorrento Therapeutics

Hmm, we can't give any reliable projection for Sorrento Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company has wild ups and downs.
  • This company is not making money.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company pays no dividend.

Inside the SRNE Numbers

SRNE Price
(Sorrento Therapeutics stock price per share)
[?] PE Ratio versus Sector 89% higher than other Healthcare stocks
[?] PE Ratio versus Industry 33% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 92%

Is Sorrento Therapeutics Stock on Sale?

Based on our analysis, we believe that you should not buy Sorrento Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy SRNE Stock?

Does Sorrento Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.